CYCLERION THERAPEUTICS INC
CYCNNASDAQ🏆 #3615 by market capUS Equity
$262.68▲ $19.18 (+7.30%)
Simulated price1h—
24h▲ 7.3%
7d▲ 7299.4%
14d▲ 7299.4%
30d▲ 6867.6%
1y▲ 11679.4%
🏦Market Cap
$17M
Small Cap
📈Revenue Growth (YoY)
-4.2%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
8.0x
Fair
Otter Score
64
Fair
Trading Snapshot
- Day Range
- $259.63 – $265.03
- 52-Week Range
- $1.03 – $8.48
- Volume
- $2.56B
- Avg Volume
- $2.63B
- Shares Outstanding
- 4.7M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $562,378
- P/E Ratio
- —
- P/S Ratio
- 8.0x
- EPS (TTM)
- $-1.37
- Dividend Yield
- —
Why Investors Own CYCN
- ✓High-growth profile — revenue up +54.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2M▲ +48.2% YoY
Gross Margin (TTM)
43.3%▲ +4.0% YoY
Operating Income (TTM)
$568,717▲ +48.2% YoY
Free Cash Flow (TTM)
$195,891▲ +48.2% YoY
About CYCLERION THERAPEUTICS INC
A company profile for CYCLERION THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
64/100
Analyst Price Target
ⓘAverage Target
$317.93
▲ +21.0% Upside
High Target$396.24
Low Target$288.25
Based on 17 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
CYCLERION THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift CYCN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
CYCLERION THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.